A detailed history of Skandinaviska Enskilda Banken Ab (Publ) transactions in Altimmune, Inc. stock. As of the latest transaction made, Skandinaviska Enskilda Banken Ab (Publ) holds 62,002 shares of ALT stock, worth $462,534. This represents 0.0% of its overall portfolio holdings.

Number of Shares
62,002
Previous 62,002 -0.0%
Holding current value
$462,534
Previous $412,000 7.77%
% of portfolio
0.0%
Previous 0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

BUY
$2.14 - $11.62 $132,684 - $720,463
62,002 New
62,002 $697,000
Q4 2022

Feb 08, 2023

SELL
$8.74 - $16.45 $19,525 - $36,749
-2,234 Reduced 5.48%
38,559 $634,000
Q3 2022

Nov 14, 2022

BUY
$10.67 - $22.41 $435,261 - $914,171
40,793 New
40,793 $520,000

Others Institutions Holding ALT

About Altimmune, Inc.


  • Ticker ALT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,025,300
  • Market Cap $366M
  • Description
  • Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...
More about ALT
Track This Portfolio

Track Skandinaviska Enskilda Banken Ab (Publ) Portfolio

Follow Skandinaviska Enskilda Banken Ab (Publ) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Skandinaviska Enskilda Banken Ab (Publ), based on Form 13F filings with the SEC.

News

Stay updated on Skandinaviska Enskilda Banken Ab (Publ) with notifications on news.